MK-6194 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-segmental Vitiligo
Conditions
Non-segmental Vitiligo
Trial Timeline
Nov 27, 2023 → Jul 30, 2025
NCT ID
NCT06113328About MK-6194 + Placebo
MK-6194 + Placebo is a phase 2 stage product being developed by Merck for Non-segmental Vitiligo. The current trial status is terminated. This product is registered under clinical trial identifier NCT06113328. Target conditions include Non-segmental Vitiligo.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06821334 | Phase 1 | Completed |
| NCT06161116 | Phase 2 | Terminated |
| NCT06113328 | Phase 2 | Terminated |
| NCT05450198 | Phase 1 | Completed |
Competing Products
8 competing products in Non-segmental Vitiligo
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR0302 Tablets + SHR0302 Base Gel + SHR0302 Placebo Tablets + SHR0302 Base Placebo Gel | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 52 |
| GIA632 + Placebo | Novartis | Phase 2 | 52 |
| PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + placebo + PF06700841 | Pfizer | Phase 2 | 51 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| Roflumilast topical 0.3% foam | Arcutis Biotherapeutics | Phase 2 | 47 |
| VYN201 Gel + Vehicle Gel | Vyne Therapeutics | Phase 2 | 44 |